Related Experiment Video
Updated: Jun 10, 2026
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
Shilpi Arora1, Irma M Gonzales, R Tanner Hagelstrom
1Pharmaceutical Genomic Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA.
Background:
Ewing's sarcomas are aggressive musculoskeletal tumors occurring most frequently in the long and flat bones as a solitary lesion mostly during the teen-age years of life. With current treatments, significant number of patients relapse and survival is poor for those with metastatic disease. As part of novel target discovery in Ewing's sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and survival of Ewing's sarcoma cells.
Results:
Four Ewing's sarcoma cell lines TC-32, TC-71, SK-ES-1 and RD-ES were tested in high throughput-RNAi screens using a siRNA library targeting 572 kinases. Knockdown of 25 siRNAs reduced the growth of all four Ewing's sarcoma cell lines in replicate screens. Of these, 16 siRNA were specific and reduced proliferation of Ewing's sarcoma cells as compared to normal fibroblasts. Secondary validation and preliminary mechanistic studies highlighted the kinases STK10 and TNK2 as having important roles in growth and survival of Ewing's sarcoma cells. Furthermore, knockdown of STK10 and TNK2 by siRNA showed increased apoptosis.
Conclusion:
In summary, RNAi-based phenotypic profiling proved to be a powerful gene target discovery strategy, leading to successful identification and validation of STK10 and TNK2 as two novel potential therapeutic targets for Ewing's sarcoma.
Insights
RNA interference screening identified STK10 and TNK2 kinases as crucial for Ewing sarcoma cell growth and survival. Targeting these kinases may offer new therapeutic strategies for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing sarcoma is an aggressive bone cancer primarily affecting adolescents, with high relapse rates and poor survival in metastatic cases.
- Current treatments are insufficient, necessitating the discovery of novel therapeutic targets.
Purpose of the Study:
- To identify novel kinase targets involved in the growth and survival of Ewing sarcoma cells using RNA interference (RNAi).
Main Methods:
- High-throughput RNAi screening was performed on four Ewing sarcoma cell lines using a siRNA library targeting 572 kinases.
- siRNAs that reduced Ewing sarcoma cell growth were identified and validated for specificity against normal fibroblasts.
- Secondary validation and mechanistic studies were conducted on promising kinase targets.
Main Results:
- Knockdown of 25 siRNAs significantly reduced the growth of all four Ewing sarcoma cell lines.
- 16 siRNAs specifically inhibited Ewing sarcoma cell proliferation compared to normal fibroblasts.
- STK10 and TNK2 kinases were identified as critical for Ewing sarcoma cell growth and survival, with their knockdown inducing apoptosis.
Conclusions:
- RNAi-based phenotypic profiling is an effective strategy for discovering therapeutic targets in Ewing sarcoma.
- STK10 and TNK2 represent novel potential therapeutic targets for Ewing sarcoma treatment.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase